RP501: Redwood Pharma makes official name for mild dry eye therapeutic development program
Following the earlier announcement Redwood Pharma has officially named the new development project for treatment of mild dry eye as RP501. This program builds upon recent clinical evidence that IntelliGel alone can provide relief to patients – evaluated by objective and subjective measures. RP501 is intended to treat a unique patient population of mild sufferers of both sexes.With unique clinical evidence strengthening its competitive positioning, RP501 will be able to compete in a growing market of mild dry eye therapies including artificial tears valued at over USD 2 billion globally